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BACKGROUND: Poor cancer survival rates in the United Kingdom are often blamed on delayed medical care. A local audit of
endometrial cancer revealed a variety of preventable delays. We surveyed practice in the South West of England to see if this was an
isolated or widespread problem.
METHODS: All 15 hospitals in the South West of England collected information prospectively from all women with endometrial cancer
over 3 months in the spring of 2009.
RESULTS: There were delays in all stages of the uterine cancer pathway. Excluding extraneous cases, 52% of women waited more than
a month and 12% waited more than 6 months to see their GP from the onset of symptoms. Almost half the cases said they were
unaware that abnormal bleeding was a symptom of cancer. Only a quarter of women had treatment within 31 days from the
outpatient visit to first definitive treatment and 18% waited more than the target of 62 days for their treatment.
CONCLUSIONS: Significant treatment delays occur because women do not report bleeding. If this is replicated throughout Britain,
approximately 1000 women per year will delay presentation for at least 3 months and 600 will wait for more than 6 months.
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Poor cancer survival rates in the United Kingdom (Sant et al, 2003,
2009; Berrino et al, 2007) are often blamed on diagnostic and
treatment delays (Coleman et al, 2011). It has been suggested that
delays might contribute to some of the differences in outcomes
between rich and poor (Coleman et al, 2001) and black and
minority ethnic populations and Caucasians (Jack et al, 2009). It
could also account for the differences in survival observed between
the United Kingdom and other comparable western European
countries. The supporting evidence is complex, occasionally
contradictory and is still incomplete. However, the overwhelming
belief is that outcomes from cancer will be improved if delays in
diagnoses can be avoided (Richards, 2009a) with the potential
(based on data obtained 10 years ago) to avoid 500 deaths per year
from uterine cancer (Abdel-Rahman et al, 2009). The National
Awareness and Early Diagnosis Initiative (NAEDI) program is one
of the key commitments of the British Government’s Cancer
Reform Strategy (Department of Health, 2007). The NAEDI
pathway (Richards, 2009b) aims to improve cancer outcomes by
examining the steps that contribute to a late diagnosis. The first
step in the pathway focuses on the low public awareness of the
signs and symptoms of cancer combined with negative beliefs
about cancer and the perceived or actual barriers to accessing
primary care services. The second step involves delays within
primary care, usually due to failure to consider cancer as the
diagnosis given all the potential competing benign causes. Delays
in secondary care are usually due to system failures. This model
encourages local care providers to eliminate significant delays at
each of these stages. However, the first problem is to identify where
any delays occur. The best way to answer this is to survey practice.
Our survey of practice began because a Macmillan Cancer-
VOICE patient advocate identified several women whose survival
chances from endometrial cancer were probably reduced because
of a long duration between first symptoms and treatment.
A subsequent retrospective audit of endometrial cancers between
2007 and 2008 in Bath, England confirmed that many women had
not been referred through the two-week wait system and some
women suffered significant delays due to poor triaging.
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women had their definitive and curative surgery within a week
from the first symptom but others waited up to a year before a
referral. Delays were due to poor patient knowledge, general
practitioner’s failure to refer or investigate cases despite a clear
history of abnormal bleeding and the poor failsafe systems
in the general gynaecological service. The first might be addressed
by funding a public health campaign, the second might be
addressed by better feedback and education to general practi-
tioners and the third was addressed by establishing failsafe systems
within the hospital unit. The South West (England) Gynaecological
Oncology Group was concerned to know if this was a small isolated
problem unique to one hospital catchment area or a far-reaching
problem throughout the region. To see if the delays in uterine
cancer diagnosis were endemic in England, the South West
Gynaecology Tumour Panel (http://www.swpho.nhs.uk) agreed
to survey the steps in the NAEDI pathway prospectively over
3 months.
MATERIALS AND METHODS
This enquiry began after a hospital audit highlighted the time
taken to treat some cases of endometrial cancer. There was a
general agreement at a meeting of the South West (UK)
gynaecological cancer tumour panel that there were other
memorable cases of delayed diagnoses in women with endometrial
cancer and that the delay might possibly have contributed to
additional treatment and a poorer prognosis. This prompted a
prospective observational study of all cases of endometrial cancer
treated in the South West of England between 1 March 2009 and 31
May 2009. Cases were identified by theatre lists, local databases,
pathology departments, coding departments and multidisciplinary
meeting records to ensure capture of all cases. Data were collected
by each participating hospital on data sheets. It focused on when
women had their first bleed, reasons for any delay in diagnosis and
the number of times women consulted their GP before endometrial
sampling. This included a questionnaire to collect the experiences
of women once they had been diagnosed with endometrial cancer.
The data were sent centrally to the South West Cancer Intelligence
Service (now the South West Public Health Observatory) for
analysis and reporting. The primary audit target was set at 96 and
91% for secondary and tertiary care referrals, respectively, for
definitive treatment to begin within 62 days from the GP’s referral.
It was felt that a survey of practice should have an accuracy of
o±5%. This meant that we required a sample size of
approximately 150 cases of endometrial cancer. This would have
been sufficient to detect a rate of delayed diagnoses with an
accuracy of ±4%, assuming negligible misreporting. Increasing
the sample size would give minimal improvement and it was
estimated that the project should take 3 months of prospective
reporting based on an annual average of 630 new cases in the
South West using data from 2002 to 2006. All hospitals that
managed endometrial cancer in 2009 in the four Cancer Networks
in the South West of England agreed to participate. The cancer
networks comprised of the Avon Somerset and Wiltshire, Dorset,
Peninsula and Three Counties Network. The NHS hospitals
comprised of Dorset County Hospital NHS Foundation Trust,
Gloucestershire Hospitals NHS Foundation Trust, North Bristol
NHS Trust, Northern Devon Healthcare NHS Trust, Plymouth
Hospitals NHS Trust, Poole Hospital NHS Foundation Trust, Royal
Bournemouth & Christchurch Hospitals NHS Foundation Trust,
Royal Cornwall Hospitals NHS Trust, Royal Devon and Exeter
NHS Foundation Trust, Royal United Hospital Bath NHS Trust,
South Devon Healthcare NHS Foundation Trust, Taunton and
Somerset NHS Foundation Trust, University Hospitals Bristol NHS
Foundation Trust, Weston Area Health NHS Trust and Yeovil
District Hospital NHS Foundation Trust.
RESULTS
All fifteen NHS hospital trusts in the four cancer networks
participated in the study. In all, 142 cases were reported (Table 1).
The age distribution of endometrial cancer was typical of the
disease. The average age was 68 (median 68; range 21–96). About a
quarter were under the age of 60 and a quarter were over the age of
75. Nineteen women with endometrial cancer did not present with
typical symptoms of abnormal bleeding to the GP. Some were
direct referrals from urologists or A&E with pain or haemorrhage,
and some had signs of metastatic disease at presentation and
others had an abnormal ultrasound scan but no symptoms. This
left 123 women with endometrial cancer confined to the uterus and
cervix who presented with abnormal vaginal bleeding.
Half waited more than a month to see their GP after their first
vaginal bleed. In all, 22% waited more than 3 months to see their
GP and 12% waited more than 6 months before they went to see
their GP. Some women approached their GP more than once. We
could not tell how many times 5 of the 123 women saw their GP,
leaving us with data on 118 women. Eighteen percent of these
women with abnormal bleeding needed to visit their GP more than
once before an investigation and one woman had to approach her
GP 4–5 times after being told that her persistent post-menopausal
bleeding was attributed to atrophy. The hospital appointments
system provided 21% of the 123 women with an appointment
within a week of the GP sending the referral letter. Thirty percent
waited more than 2 weeks and 13% waited over a month.
Some women were able to give reasons for these delays. For
example, 85 commented on their abnormal uterine bleeding and
approximately half (n¼41) said that they had no idea that it was a
sign of possible cancer. Ten women (out of 72 responders)
admitted that they delayed approaching their GP because they
were scared about the possibility of cancer. Three out of 75 delayed
seeking help because they felt that it had been difficult to access
the GP, either because their own GP was on holiday or because full
time work coincided with the surgery opening hours.
Eleven out of 83 responders reported that their GP did not make
an urgent referral to the rapid access gynaecological services
because their GP had told them that their bleeding was normal.
One woman was told to watch and wait for a month before being
referred. Seven out of 79 responders had a delay and they thought
that this was because their GP did not use a two-week wait service.
In fact, a review of the case notes showed that about a third of the
women were not referred through the two-week wait system. Fifty
five percent of those referred using the general referral system
waited more than 2 weeks and a quarter waited over a month to be
seen. In contrast, 89% of women were seen within 2 weeks if the
cancer referral two-week wait referral system had been used
(w
2¼24.5518; df¼3; Po0.0001), but that still meant that 11%
waited more than 2 weeks to be seen. Four percent waited a month
or more.
Once a woman had seen her GP, the next step in the NAEDI
pathway was to have an endometrial biopsy, diagnosis and
treatment. Of the 142 cases, 24 cases do not contribute to this
part of the analysis because they were either emergency admis-
sions, asymptomatic and diagnosed because a coincidental
ultrasound was abnormal, or presented with symptoms of
advanced disease. Only a quarter (30 of the 118) women had their
first definitive treatment, usually hysterectomy within 31 days
from the outpatient visit. Eighteen percent waited more than the
target of 62 days for their treatment. Not all cases were
straightforward. For example, one woman needed three biopsies
before a diagnosis was made. One surgeon saw and diagnosed a
cancer within a week but was told by hospital management that the
target was 62 days and the cancer surgery had to be delayed so that
the operating time could be devoted to sterilisation procedures
because these women risked breeching the national 19-week
waiting target. The waiting time for treatment was similar
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referred using the suspected cancer or two-week wait criteria were
treated within 2 months.
DISCUSSION
Some women with endometrial cancer in the South West of
England experienced delays in their cancer journey due to poor
health education, inefficient primary care referral practices
and delays in initiating hospital treatment. The most significant
observations are that about half of the women with cancer claimed
to have no idea that abnormal vaginal bleeding could represent
cancer, half took more than a month to see their GP from the onset
of symptoms, a third of GPs failed to triage cases of abnormal
bleeding to a cancer service and 18% of women waited longer than
the target of 62 days for their treatment. Delays were due to
multifactorial issues involving all aspects of the NAEDI pathway.
The delays in treatment at the hospital level were often for good
reason and the vast majority of women are unlikely to have had
their outcome affected adversely. The poor triaging by some GPs
despite classic symptoms caused statistically significant delays.
The occasional GP who failed to refer or investigate a woman as
soon as she presented will, in retrospect be embarrassed, but a
single example throughout the South West of the country probably
represents a single clinical error rather than a system failure. It is
delays caused by patients that are likely to cause the most
important contribution to a potentially dangerous long symptom
to treatment interval. The key to improving outcomes might be to
focus resources on the one in eight women who waited more than 6
months before they went to see their GP. Ignorance of important
symptoms and reluctance to attend the doctor are long-standing
problems with the British population. Numerous surveys show that
the British public are poorly educated in health issues and cancer
risk symptoms (Wardle et al, 2001) and are inhibited by barriers to
help seeking such as difficulty making an appointment, worry
about wasting the doctor’s time and worry about what would be
found (Robb et al, 2009). There are numerous suggested strategies
for improving public knowledge and tools to evaluate these
interventions (Stubbings et al, 2009) but a systematic review of the
world literature (Austoker et al, 2009) shows that there is very little
evidence that interventions are effective at promoting earlier
presentation. Exceptions are breast cancer (Catalano et al, 2003;
Gabram et al, 2008), malignant melanoma (Rossi et al, 2000;
MacKie et al, 2003), retinoblastoma (Leander et al, 2007) and
tobacco use. However, the absence of evidence of an effect in
uterine cancer is not evidence of ineffectiveness. Public informa-
tion strategies probably work in breast cancer and melanoma care
and this suggests that a greater public awareness about the
seriousness of postmenopausal bleeding might be effective. An
example of an intensive education campaign is the Eve Appeal
(www.eveappeal.org.uk). This may lead to greater cancer aware-
ness and earlier presentation over the short term but the effect may
not be sustained and we do not know how to design a campaign to
make it effective.
This is the first British survey we could find that focuses on
endometrial cancer and other regions will need to see if the results
are mirrored elsewhere. The strength of the study is that it reflects
current practice throughout a large region, all women were
captured and it was prospective. This minimises sampling bias,
reduces recall bias and the high ascertainment rate implies that the
results will be internally valid. External validity is more difficult to
establish because of the lack of other similar work but a Danish
survey of all gynaecological cancers also highlighted diagnostic
delays in all parts of the diagnostic pathway (Robinson et al, 2009).
Although the UK has national targets and uniform referral health
care systems, there will be regional variations because attitudes,
education and resources vary. The data will not be timeless and
will not reflect care outside the NHS. Another problem is that we
do not know how to respond to our findings. On the face of it, this
study suggests that a campaign to get GPs to use the fast track
cancer referral pathway and a public health campaign might save
lives. A greater use of the fast track system might swamp resources,
dilute expertise and delay the diagnosis in higher risk women.
Finally, we don’t know if the prompt diagnosis of uterine cancer is
important. With the exception of breast cancer (Richards et al,
1999), the linkage between delay and poor survival has been
difficult to prove from observational studies. Trial data in this area
are lacking and observational studies often show no association or
negative ones. Indeed a survey in Scotland reported the apparently
paradoxical finding that patients with longer delays may have
better survival rates (Crawford et al, 2002). How might this be
explained? To quote Mike Richards, National Clinical Director for
Cancer, most of the reported studies fail to report the nature of the
first symptom and patients with the most sinister symptoms in
terms of prognosis may present rapidly to health services, while
those with other symptoms may still have early-stage disease even
after several months. The logical explanation for this is that
doctors fast track patients with more obvious and advanced
cancers (Neal, 2009). This paradox is not unique to cancer care
(Turner and Al-Chalabi, 2002). Therefore, it seems sensible to
assume that a 6 months delay is dangerous. If this data were
reflected across the country, approximately 1000 women per year
delay presenting to their GP by at least 3 months and 600 wait over
6 months. We have invested enormous amounts of finance into
improving cancer pathways. More investment is likely to suffer
from diminishing returns. Perhaps it is time to invest in public
education.
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32–62 days 67 (57)
462 days 21 (18)
Not presenting through an outpatient clinic 15
NK 9
Abbreviations: NAEDI¼National Awareness and Early Diagnosis Initiative; NA¼Not known.
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